These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 14709965)

  • 1. An open-label trial of bupropion in the treatment of pathologic gambling.
    Black DW
    J Clin Psychopharmacol; 2004 Feb; 24(1):108-10. PubMed ID: 14709965
    [No Abstract]   [Full Text] [Related]  

  • 2. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
    Black DW; Arndt S; Coryell WH; Argo T; Forbush KT; Shaw MC; Perry P; Allen J
    J Clin Psychopharmacol; 2007 Apr; 27(2):143-50. PubMed ID: 17414236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.
    Vulink NC; Denys D; Westenberg HG
    J Clin Psychiatry; 2005 Feb; 66(2):228-30. PubMed ID: 15705009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion sustained release for panic disorder.
    Simon NM; Emmanuel N; Ballenger J; Worthington JJ; Kinrys G; Korbly NB; Farach FJ; Pollack MH
    Psychopharmacol Bull; 2003; 37(4):66-72. PubMed ID: 15131517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion therapy for pathological gambling.
    Padala PR; Madaan V; Sattar SP
    Ann Pharmacother; 2007 Mar; 41(3):529. PubMed ID: 17341539
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended treatment with bupropion SR for cigarette smoking cessation.
    Killen JD; Fortmann SP; Murphy GM; Hayward C; Arredondo C; Cromp D; Celio M; Abe L; Wang Y; Schatzberg AF
    J Consult Clin Psychol; 2006 Apr; 74(2):286-94. PubMed ID: 16649873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body dysmorphic disorder treated with bupropion: cases report.
    Nardi AE; Lopes FL; Valença AM
    Aust N Z J Psychiatry; 2005; 39(1-2):112. PubMed ID: 15660717
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Moss EL; Simpson JS; Pelletier G; Forsyth P
    Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
    Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
    Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline and bupropion sustained-release combination therapy for smoking cessation.
    Ebbert JO; Croghan IT; Sood A; Schroeder DR; Hays JT; Hurt RD
    Nicotine Tob Res; 2009 Mar; 11(3):234-9. PubMed ID: 19246427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptual disturbances associated with low-dose bupropion sustained-release treatment.
    Liu CY; Chien YS
    J Clin Psychopharmacol; 2007 Oct; 27(5):543-4. PubMed ID: 17873707
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wellbutrin versus generic bupropion.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):54-5. PubMed ID: 18617874
    [No Abstract]   [Full Text] [Related]  

  • 17. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
    Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2007 Sep; 62(6):652-7. PubMed ID: 17445781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.
    Dalsgareth OJ; Hansen NC; Søes-Petersen U; Evald T; Høegholm A; Barber J; Vestbo J
    Nicotine Tob Res; 2004 Feb; 6(1):55-61. PubMed ID: 14982688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.